Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: DrugBank:APRD00631 (Gel)
 14,881 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The new substance Etofenamat (Rheumon Gel) is effective percutaneously in the treatment of rheumatic diseases. The gel is shown to be an effective antiphlogistic and analgetic, especially in vertebragenic diseases. The results of treatment of 81 patients are summarized. In a total of 56 patients, use of Etofenamat led to an evident improvement, for example, freedom from pain. Treatment for up to 9 days, eliminated pain in 73 of the 81 patients. In 28 patients out of 38, the mobility of joints was favourably effected. No side effects were observed.
 ...
PMID:[Experiences with a new percutaneously effective antirheumatic preparation]. 33 54

Clinical trials with 2-(2-hydroxyethoxy)-ethyl-N-(a,a,a-trifluoro-m-tolyl)-anthranilate (etofenamate, active principle of Rheumon Gel) were carried out on a total of 69 patients suffering from extra-articular rheumatic complaints and painful spinal syndromes as well as from post-operative and post-accident complaints. Criteria for assessment included spontaneous pain, pressure pain and pain on movement and also limitation in joint mobility. The new gel formulation proved to have a good analgesic efficacy both in a double blind trial against placebo gel and the open study. Those patients treated with Rheumon Gel showed improvement in the symptoms spontaneous pain and pain on movement, in a large number of which patients showing improvement, in a large number of which patients showing improvement the spontaneous pain was completely eliminated. The differences in therapeutic effect compared to the placebo group as well as those of the final clinical assessment were statistically significant. Particularly good therapeutic results were observed in extra-articular rheumatic complaints and in activated arthroses. The skin tolerance of Rheumon Gel was found to be excellent. The gel form permits good and rapid penetration through the skin. The nursing staff also willingly administered the product because of its pleasant protective properties for skin and clothing.
 ...
PMID:[Experience with a locally applicable antirheumatic (author's transl)]. 33 57

Essaven Gel contains aescin, heparin and essential phospholipids (EPL). It was administered locally in 15 patients suffering from thrombotic inflammation of tibial superficial veins. The effect of Essaven Gel on prostaglandin synthetase activity was also studied. In 12 patients a positive result was obtained in the form of anti-inflammatory action, diminution of pain, edema, excessive warmth and flushing. The anti-inflammatory action proceeds without any participation of prostaglandin synthetase.
 ...
PMID:Local treatment of thrombophlebitis with essaven gel. 82 36

This two-phase experiment assessed the effects over time of a solution containing 1.09% sodium fluoride, .40% stannous fluoride, and .14% hydrogen fluoride (.717% fluoride solution, DentinBloc) on pain associated with dentinal hypersensitivity. During phase I, 30 subjects demonstrating dentinal hypersensitivity to a blast of cool air were divided into three double blind experimental groups. After baseline data were collected for all subjects, one group was instructed to apply the .717% fluoride solution twice a day. A second group was instructed to apply a gel containing .04% stannous fluoride (Gel-Kam) twice a day. A third group was instructed to apply distilled water. Each subject was assessed at 2, 4, 8, and 16 weeks utilizing the "method of limits" with a standardized, repeatable cold thermal stimulus. The results of a two factor repeated ANOVA indicated that those subjects who applied the .717% fluoride solution reported significantly less sensitivity at the 2-week period than the other groups (P < .05). In addition, those subjects whose solution contained the 0.4% stannous fluoride reported significantly less sensitivity at the 4- to 8-week periods (P < .05). Phase II of the study assessed the .717% fluoride solution on a more precise time course. These included: immediately, 15 minute, 1 day, 1 week and 2 weeks. A one factor repeated ANOVA revealed that this effect presented 15-minute post application (P < .05) and continued throughout the testing periods. It was concluded that the fully active 0.717% fluoride solution was an effective agent in the control of dentinal hypersensitivity after two 1-minute applications.
 ...
PMID:Effect of a fluoride solution on dentinal hypersensitivity. 130 75

A comparison of a system of moist wound dressings to traditional normal saline wet-to-dry dressings was conducted on OB/GYN patients with open abdominal incisions. The moist wound products included in this study were a hydrogel (Intrasite Gel) and a foam wound cavity filler (Allevyn), manufactured by Smith & Nephew United, Inc. of Largo, FL, and a transparent cover (Bioclusive), manufactured by Johnson & Johnson Medical, Inc. of Arlington, TX. The results indicated that those incisions treated with the moist wound environment dressings experienced fewer complaints of pain, a decrease in healing time and a significant cost savings.
 ...
PMID:A comparison of wound environments. 148 22

281 patients with extra-articular rheumatic disorders (enthesiopathy, bursitis, tendinosis, fibrositis) and moderate or severe localized pain during rest or movement in shoulder, neck, elbow or knee were randomized into groups and treated for 14 days in a double blind study with either 1 g Felbinac Gel 3% (biphenyl acetic acid) three times daily (N = 142) or with the gel formulation only (N = 139). In 50% of the patients treated with Felbinac Gel compared to 29% of the placebo treated patients (p = 0.001), the investigator assessed the global therapeutic success to be good or very good. The magnitude of complaints judged on the basis of a visual analogous scale by patients and doctor showed a significant improvement in pain reduction during rest or activity after 14 days of treatment in the Felbinac group. The rheumatic complaints diminished equally according to patient judgement in both treatment groups and the concomitant use of paracetamol was low in both groups. No significant side-effects or changes in laboratory parameters were observed during therapy. Felbinac Gel therefore is suitable for a low-risk topical therapy of soft tissue rheumatic disorders.
 ...
PMID:[Felbinac gel for treatment of localized extra-articular rheumatic diseases--a multicenter, placebo controlled, randomized study]. 187 42

Four commercial gel preparations of topical anti-inflammatory agents have been assessed in six animal models commonly used to determine the biological activity of non-steroidal anti-inflammatory agents for systemic administration. Only UV-induced erythema of the skin, adjuvant induced arthritis and the measurement of vascular permeability proved suitable for differentiation of the potency of the four topical agents. Carrageenin-induced paw oedema, the cotton pellet test and the assessment of the pain threshold according to Randall and Selitto were of little value. The effects of the gel preparation of diclofenac (CAS 15307-86-5) diethylammonium (Voltaren Emulgel) were comparable to two preparations containing 1% and 5% active ingredient, respectively. Gel 4 showed low overall activity. The experiments demonstrated that some of the models used for the assessment of anti-inflammatory agent for systemic administration proved suitable for the testing of topical preparations and that percutaneous absorption was insufficient to elicit anti-inflammatory effect in the animals at sites remote from the site of application.
 ...
PMID:Assessment of topical non-steroidal anti-inflammatory drugs in animal models. 229 49

Rheumon-Gel was used for therapy of 51 patients with rheumatoid arthritis. It has been shown that the drug has a marked antiinflammatory and analgesic action, a positive effect on a number of subjective (pain in the joints and constrained movements in the morning), objective (body temperature, edema and joint function), and laboratory (leucocyte count, ESR, C-reactive protein, titer of antistreptolysin-O and antistreptohyaluronidase) indices and therefore it can be recommended for multimodality therapy of rheumatic patients, particularly of those with rheumatoid arthritis combined with G. I. tract diseases when the use of most of the antirheumatic drugs is counterindicated.
 ...
PMID:[Topical use of Rheumon-Gel in the combined treatment of patients with rheumatoid arthritis]. 344 80

Met-enkephalin immunoreactive material content was found to be decreased in the cervical and thoracic segments of the spinal cord from rats aged 25 months as compared to young, 3-month-old, rats. No age-related variations were detectable at the lumbar level. Bio-Gel P 30 column chromatography of thoracic segment extracts indicates that the composition of the immunoreactive material is similar in the two age-groups investigated. At the thoracic level opiate receptor binding was also measured. Opiate receptor number is increased in the thoracic segments of the spinal cord from older rats. These age-related changes in immunoreactive Met-enkephalin content and opiate receptor number at spinal levels may contribute to determine an altered pain sensitivity during aging.
 ...
PMID:Age related changes of enkephalin in rat spinal cord. 629 70

Formation of the ternary complex Met-tRNAi X eukaryotic initiation factor (eIF) 2 X GTP from eIF-2 X GDP requires exchange of GDP for GTP. However, at physiological Mg2+ concentrations, GDP is released from eIF-2 exceedingly slowly (Clemens, M.J., Pain, V.M., Wong, S.T., and Henshaw, E.C. (1982) Nature (Lond.) 296, 93-95). However, GDP is released rapidly from impure eIF-2 preparations, indicating the presence of a GDP/GTP exchange factor. We have now purified this factor from Ehrlich cells and refer to it as GEF. CM-Sephadex chromatography of ribosomal salt wash separated two peaks of eIF-2 activity. GEF was found in association with eIF-2 in the first peak and co-purified with eIF-2 under low salt conditions. It was separated from eIF-2 in high salt buffers and further purified on hydroxylapatite and phosphocellulose. Gel electrophoresis of our purest preparations showed major bands at 85, 67, 52, 37, 27, and 21 kDa. Purified GEF increased the rate of exchange of [32P] GDP for unlabeled GDP 25-fold but did not function with phosphorylated eIF-2 (alpha subunit). The factor also stimulated markedly the rate of ternary complex formation using eIF-2 X GDP as substrate with GTP and Met-tRNAi but not using phosphorylated eIF-2 X GDP as substrate. eIF-2 is released from the 80 S initiation complex with hydrolysis of GTP. If eIF-2 X GDP is actually the complex released, then GEF is absolutely required for eIF-2 to cycle and it is therefore a new eukaryotic initiation factor. Furthermore, the inability of GEF to utilize eIF-2 (alpha P) X GDP explains how phosphorylation of eIF-2 can inhibit polypeptide chain initiation.
 ...
PMID:A GDP/GTP exchange factor essential for eukaryotic initiation factor 2 cycling in Ehrlich ascites tumor cells and its regulation by eukaryotic initiation factor 2 phosphorylation. 655 52


1 2 3 4 5 6 Next >>